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Proton therapy has great advantage over photon therapy in head and neck cancer 
radiotherapy due to the absence of exit dose from the proton beams. However, proton 
therapy is much more sensitive to anatomical changes and setup uncertainties, which 
results in up to 40% re-planned rates in head and neck cancers (H&N). Using clinical 
data from over one hundred H&N patients treated with proton therapy, this project aims 
to create a neural network which will be trained with patients’ clinical, radiographic, and 
dosimetric information, and will be able to evaluate plan quality and predict the 
probability of plan adaption. This will be a great tool to guide clinical practice in proton 
therapy for not only head and neck cancer treatments, but also other treatment sites that 






CHAPTER 1. INTRODUCTION 
1.1 Motivation 
H&N cancers are a diverse group of tumors with many pathologies and etiologies. They 
cause an estimated 330,000 deaths worldwide (1). H&N cancers account for 3% of all 
cancers and have various subsites that include the salivary glands, oral cavity, and 
pharynx (2,3). Though there is great diversity within H&N cancers, they are all very 
difficult to treat because of tumor proximity to critical organs.  
Radiation therapy is used in conjunction with surgery and chemotherapy to combat H&N 
tumors, even being able to treat early-stage tumors on its own. Intensity modulated 
radiation therapy (IMRT), a type of photon therapy, is a common choice of treatment for 
H&N cancers. Intensity modulated proton therapy (IMPT) has become an increasingly 
popular choice for H&N cancer treatment because of their highly accurate dose local 
deposition and steep dose gradients. 
In cases where anatomy changes or setup uncertainties are too severe, the original 
treatment plan is no longer suitable, and adaptive therapy is necessary. Adaptive therapy 
is a concept that was originally introduced for photon therapy over 20 years ago (4). 
Studies have shown that photon adaptive therapy has increased the sparing of organs at 
risk (OARs) in H&N sites (5,6). 
Adaptive therapy is much more frequently needed for proton treatment. It has been 
shown that adaptive therapy is necessary for many proton sites (7-11).  At the Emory 
Proton Therapy Center (EPTC), 30-40% of H&N cases are re-planned at least once 
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during their course of treatments. It takes up to 5 days for a re-plan adaptation to be used 
for treatment. H&N re-plans make up most re-plans across all sites at our institution for 
all the treatments in 2020, as shown in Figure 1.  
 
Figure 1 Re-plan cases across all treatment sites at EPTC in 2020 
1.2 Photon vs. Proton Therapy 
Proton therapy has several advantages over conventional photon therapy. In photon 
therapy, the dose-vs-depth curve continuously and exponentially decreases through the 
patient, which causes damage to healthy tissue distal to the target. In proton therapy, 
however, there is a sharp dose fall-off and the maximum dose is at the end of their range 
(12). The linear energy transfer of protons remains mostly constant until they start to 
significantly slow down, leading to a rapid deposition of energy at the end of their 
particle track known as the Bragg peak (13). The differences between the dose deposition 
of photons and protons are shown in Figure 2.   
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Figure 2 - Depth Dose Curves for 6MV Photons and 120MeV Protons 
The position of the Bragg peak is a function of the proton energy and the water 
equivalent thickness (WET). WET is calculated from the stopping power relative to water 
(RSP). RSP is derived from the planning computed tomography image (pCT) using the 
well-established stoichiometric calibration method that converts HU to density to RSP 
(14).  However due to non-unique density to RSP conversion and many other 
uncertainties in computed tomography (CT) imaging, +/-3.5% range uncertainties are 
adopted to account this process, with 95% confidence level. At EPTC, protons are 
delivered using the pencil beam scanning (PBS) technique, in which proton spots are 
scanned across the target. Various proton energies with proper weighting are used to 
create a spread-out Bragg peak (SOBP) to cover the target in the beam direction. 
Proton therapy provides tumor coverage while offering more sparing for critical organs 
than photon therapy. In sites where the proximity of critical structures is a concern, 
protons are the preferred choice. For these reasons, IMPT has become common in the 
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treatment of head and neck cancer. However, IMPT is much more sensitive to inter-
fractional and intra-fractional changes. 
1.3 Inter-Fractional and Intra-Fractional Changes in H&N Radiotherapy 
Intra-fraction changes (organ motion, patient motion, breathing) and inter-fraction 
changes (position uncertainties and anatomic changes) can significantly alter the dose 
distribution near the targeted tumor boundary in IMPT. H&N sites typically have 
minimum intra-fractional changes. Inter-fractional changes are much more prevalent, and 
there are several ways these are mitigating.  
Inter-fraction changes are lessened with immobilization devices such as vacuum casts as 
well as taking regular images to monitor the patient’s anatomy. H&N cancer patients 
undergo several types of anatomical changes through the course of their treatments. 
These include target shrinkage, weight loss/gain, cavity filling changes, etc. (15-17). 
Several models have been designed to predict the weight loss of the patient (18-20).  
1.3.1 Anatomy Changes  
During treatment course, anatomy changes are monitored with cone beam CTs (CBCTs) 
and quality assurance CTs (QACTs). An example of the impact of anatomy changes on 
proton therapy plans is shown in Figure 3.  
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Figure 3 – Image overlay between the pCT and QACT (left, blue: extra tissue in the 
pCT, brown: extra tissue in QACT), dose distribution in pCT (center), and QACT 
(right). White circle emphasizes > 110% dose increase, while the black circle 
includes the under coverage for the CTV54Gy 
The left image shows the pCT with solid contours (blue) overlayed with a QACT taken a 
month later with dashed contours (orange). The blue and purple contours represent the 
high dose level and intermediate dose level clinical target volumes (CTVs), which appear 
smaller on the QACT. Even in just a month, this patient has undergone large changes, 
especially the shrinkage of the right and right anterior face. Also, the posterior neck tissue 
does not fit the neck rest cushion at the treatment site. The middle image shows the initial 
plan on the pCT, which has adequate coverage of both CTVs. The right image shows the 
initial plan on the QACT, which has changed significantly. In the white circle, there is a 
hot spot and there is a loss of coverage in the black circle. Hot spots and losses of 
coverage come from the shift in the Bragg peak positions of proton spots, which has to be 
addressed with plan adaptation. 
1.4 Neural Networks and Their Applications in Radiotherapy 
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Neural networks are computational models made of multiple layers of data processing. 
Given adequate training data, these models can learn the relationships between 
independent and dependent variables through modifying model parameters using a back 
projection algorithm. With enough layers, neural networks can be sensitive to small 
changes and unsensitive to large variations in the data. They can achieve results 
comparable to traditional statistical models, and they are used for various types of 
problems such as pattern recognition and classification (21).  
1.4.1 Neural Network Background 
The structure of a neural network is shown in Figure 4. 
 
Figure 4 - Example Neural Network Structure 
Each layer consists of several nodes. The input layer takes in the independent variables. 
The hidden layer is used for data processing, and the output layer is the prediction the 
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model makes. In classification problems, which is what neural networks are used for in 
this project, the output layer produces the categorical class label.  
Each connection between the nodes has a weight wij. The input of node j in the first 
hidden layer, Ij, is calculated from the sum of the product of the weights and their 
corresponding input variables, xi shown in Equation 1.  




This input is then put into an activation function f. Activation functions in hidden layers 
are used to help the neural network learn complicated relationships between the data. The 
output of the node j, Oj is shown in Equation 2.  
𝑂𝑗 = 𝑓(𝐼𝑗) (2) 
The choice of activation functions in the output layer depends on the desired output. For 
classification problems, the softmax function, defined in Equation 3, is used. 




Where ?⃗⃗? is the vector of outputs and n is the number of outputs. Softmax transforms the 
outputs such that their total equals 1. For multiclass classification, these transformed 
outputs represent the probability of each output. The neural network then choses the 
output with the highest probability.  
1.4.2 Neural Network Training 
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Neural networks “learn” from examples given to them. In order to effectively train them, 
the training data must be representative of the situation being modeled. 
The values of the weights in a neural network are given an initial value. Using the inputs 
taken from the training data, it produces an output. The error between this predicted 
output and expected output is then calculated. The error is given to a backprojection 
algorithm, which adjusts the values of the weights. Every training example adjusts the 
weights, and, eventually, the neural network “learns” the relationship between the data. 
The more data given to a neural network, the more powerful the predictive power. 
However, neural networks can often be overfitted to the data, making them useless in 
cases not found in the data set.  
The choice of backprojection algorithm, scaling of the independent variables, activation 
functions, and network structure are all important considerations when designing a neural 
network.  
1.4.3 Limitations and Variations 
When models have several layers, training a neural network can take a significantly long 
time. They also require amounts of data in order to be adequately trained. They can also 
become over correlated to the training data, making the model useless for cases outside 
the training data. To tell when a neural network is overfitted, training data is split into a 
training set and a testing set. The testing set is used to see how well the model fits new 
data, and it validates the predictive power of the neural network.  
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Because the split of the data is random, neural networks trained with the same data will 
produce different results. It is necessary to train several different ones to find the best 
option. 
1.4.4 Using Neural Networks for Re-Plan Prediction 
Neural networks have been applied to radiotherapy for dosimetric prediction (22-24). 
This project proposes that a neural network can be designed and used for re-plan 
prediction. Its training data would come from clinical features and dosimetric parameters 
from the initial plans of patients treated at our institution and output whether new patients 
will need a re-plan. This pre-treatment neural network could then be used by dosimetrist 
and physicists to evaluate the plan prior to treatment and improve the plan when 
necessary, potentially reducing the re-plan rates. 
A separate neural network could be used to monitor the re-plan chance during treatment. 
This on-line prediction model could be designed by including the changes in WET as an 
input.  
With these neural networks, this project aims to reduce re-plans caused by anatomical 
changes in H&N cancer.  
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CHAPTER 2. METHODOLOGY 
2.1 Data Collection 
The data used to train the prediction model were gathered from 229 H&N patients treated 
at our institution. Patients spanned 24 different H&N sites, and the most common were 
the oropharynx (40 cases), lip and oral cavity (17 cases), and nasal cavity/sinuses (16 
cases). 40% of patients were re-planned. 
2.1.1 Treatment Planning Considerations 
At our institution, a 5-beam arrangement is used to treat bilateral H&N patients, which 
make up 61% of our data. A 3-beam arrangement is used to treat unilateral H&N patients, 
which make up 39% of our data. These arrangements are shown in Figure 5. Any portion 
of the target is typically covered by at least two beams, which contribute to the total dose.  
 
Figure 5 – Typical beam arrangements in H&N proton therapy. Bilateral 5 beam 
arrangement (left). Unilateral 3 beam arrangement (right). 
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Most patients are treated with up to 3 dose levels. The highest level is used for the 
treatment of the gross tumor site or surgical beds. The other dose levels are used to treat 
lymph nodes, with the higher dose level typically being used on the lymph node closer to 
the gross tumor site. The number of fractions and dose levels vary between patients, but 
typical ranges for these levels are 66-70 Gy, 57-61 Gy, and 53-55 Gy treated for 33-35 
fractions. All 3 levels are delivered with simultaneous integrated boost (SIB). The 
coverage goal for each level is D98 = 100%. 
Critical structures in HN plans include the spinal cord, brain stem, oral cavity, parotid 
glands, and optic chiasm. The constraints for these structures at our institution are shown 
in Table 1.  
Table 1 - Critical Structures and Their Constraints in H&N Radiotherapy 
Critical Structures Constraints 
Spinal Cord <45 Gy at .03cc  
Brain Stem <54 Gy at .03cc <60 Gy at .03cc 
Oral Cavity Mean dose < 12 Gy Mean dose < 35 Gy 
Parotid Glands Mean dose < 26 Gy < 50% volume at 30 Gy 
Optic Chiasm <54 Gy at .03cc  
A ±3.5% range uncertainty combined with ±3 mm setup shifts on 3 coordinate directions 
(superior/inferior, anterior/posterior, left/right) was used in robust optimization. For 
robust evaluation, robustness scenarios consisted of 12 scenarios with setup shifts with 
range uncertainty and 2 scenarios with just the range uncertainty.  
2.1.2 Clinical Features 
15 clinical features were manually gathered from the patients using our clinical database. 
These features are shown in Table 2.  
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Table 2 – Clinical Features Obtained from H&N Patients 
Clinical Features 
Sex Age Re-plan (Y/N) Reason for Re-plan 
Site Stage TNM p16 Value 
Had Surgery (Y/N) Surgery Margins Surgery Date Planner 
pCT and QACT 
simulation date 
Had concurrent chemotherapy (Y/N) 
Type of therapy 
(definitive/palliative) 
 
2.1.3 Dosimetric Features 
Various dosimetric features were obtained from patients in the treatment planning system 
(TPS) Raystation 9A (RaySearch Laboratory, Stockholm, Sweden). These include beam 
dose heterogeneity index (BHI) and several robustness features. These will be discussed 
in the next sections. Dosimetric features were chosen to represent plan quality and were 
gathered from the initial plan and robust evaluation plans. A Python script running in the 
TPS was made to obtain the data. 
2.1.4 Beam Dose Heterogeneity Index (BHI) 
There are several ways to define heterogeneity. In this project, BHI was defined as the 
ratio of the max beam dose to its expected contribution, which was assumed to be half the 






Where Dmax and Dpre are the max dose and prescription dose, respectively.The dose at 
several small volumes (.03cc, .1cc, .2cc, .5cc) was used to represent the max dose and 
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dose heterogeneity. The BHI was calculated for every beam. This was used to calculate 
the max BHI and mean BHI. 
2.1.5 Robustness Features 
Plan robustness was evaluated with several features gathered from the highest dose level 
CTV.  
The shoulder of the robust evaluation dose volume histogram (DVH) of the CTVs is 
shown in Figure 5. The nominal plan is shown in the dashed line, and the robustness 
scenarios are shown in the dotted lines. Several robustness features were obtained from 
the shoulder of the dose-volume histogram used for robust evaluation. Success rate was 
defined as the fraction of robustness scenarios where V100 was greater than 95%. The 
mean V100 CTV and its deviation from the nominal plan, V100 change, defined in 
Equation 5, were also gathered.  







Where n is the number of robustness scenarios. 
The last robustness feature, mean max dose change, defined in Equation 6, was defined 
as the max dose’s average deviation from the nominal plan over all the scenarios.  
𝑀𝑒𝑎𝑛 𝑀𝑎𝑥 𝐷𝑜𝑠𝑒 𝐶ℎ𝑎𝑛𝑔𝑒 =
1
𝑛







Figure 6 - Shoulder of CTV DVH in robust evaluation with nominal plan (dashed) 
and robustness scenarios (solid).  
2.1.6 Water Equivalent Thickness Calculation 
Anatomical changes are a common cause of re-plans. To measure the anatomical changes 
during treatment course, WET is calculated. WET is the most direct measure of anatomy 
changes. Figure 7 shows how WET is calculated with a python script in the TPS. Using 
the image in Figure 7a, the script uses a table to convert HU to RSP. Then, for each 
beam, the image is rotated by the gantry angle. This moves the image into beam eye’s 
view (BEV).  
A BEV image for a 45° beam is shown in Figure 7c.  To represent the beam path through 
the image, WET was integrated along the columns of the BEV image. This shown in 
Figure 7d. The integrated image was then unrotated as shown in Figure 7e. 
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Once the unrotated WET CTs for every beam were generated, the WET of the 
optimization structure corresponding to each beam were found. These structures 
represent the portion of the CTV that each beam treats. For each beam, its WET was the 
average WET of all the points on this contour.   
The WET script was applied to the pCT and QACTs. The WET of the same beam 
specific targets in pCT and the differences with the QACT WETs were calculated. This 
represented patient changes in the beam path between the simulation and the QACT. 
 
Figure 7 - WET Script Workflow 
 
 16 
2.2 Statistical Analysis 
IBM SPSS v27 was used to perform statistical analysis on the data. Statistical 
significance was found to see which features were related to re-plans.  To determine the 
significance, several statistical tests were used. The choice of test depended on the 
distributions of the data. 
Since most of the data were not normally distributed, nonparametric tests were used. All 
these data were independently sampled, so a Mann-Whitney U test was used. For 
categorical data, a chi-square test was used to find significance.  
2.3 Neural Network Design 
2.3.1 Network Structure 
The neural networks used for re-plan prediction were designed in IBM SPSS v27 
software using its multi-layer perceptron (MLP) function. For both the pre-treatment and 
on-line models, the structure consisted of an input layer, two hidden layers of 10 and 8 
nodes, respectively, and an output layer. A sigmoid activation function was used for the 
hidden layers and a softmax activation function was used for the output layer. The design 
of the on-line prediction model is shown in Figure 5. Input 1 to 20: 1) dosimetrist, 2) 
tumor site, 3) sex, 4) whether the patient had surgery, 5) whether the patient had 
chemotherapy, 6) time between surgery and CT simulation, 7) tumor stage, 8) T stage, 9) 
N stage, 10) age, 11) surgery margins, 12) p16 value, 13) max BHI, 14) mean BHI, 15) 
mean max dose change, 16) success rate, 17) mean V100, 18) mean V100 change, 19) 
time between CT simulation and QACT, 20) WET % change between pCT and first 
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QACT. Output of 0 represents no re-plan, and output 1 represents a re-plan. The pre-
treatment model did not include inputs 19 and 20, but it was identical to the on-line 
model otherwise.  
 
Figure 8 - Multilayer Perceptron Neural Network for Re-Plan Prediction Structure 
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2.3.2 Training Data 
Both models were trained with the dosimetric and clinical features previously mentioned. 
The data was partitioned into 70% training and 30% testing. Due to patients not passing 
the export scripts for BHI, robustness, and WET, the training data used is much less than 
the total number of patients. The initial re-plan prediction model was trained with 53 
cases, and the on-line prediction model was trained with 49.  
2.3.3 Evaluating Performance 
Performance was analysed using a classification table, prediction important index, and 
receiver operating characteristic (ROC) curves. Classification tables display the true 
positives (TP), true negatives (TN), false positives (FP), and false negatives (FN) of both 
the training and testing sets. These are used to calculate sensitivity, also called true 
positive ratio, and specificity, also called the true negative ratio. Sensitivity and 
specificity are defined in Equations 7 and 8, respectively. To test the impact of the inputs, 













CHAPTER 3. RESULTS 
3.1 Data Analysis 
3.1.1 Numerical Features 
All numerical features other than age were normally distributed. Because of this, non-
parametric Mann Whitney U-Tests were used for all numerical variables. The null 
hypothesis was that there was no correlation between the features and re-plans, and the 
alternative hypothesis was that there was a correlation. A 95% confidence interval was 
used to determine significance.  
Table 3 shows the mean, standard deviation, and p-value for all numerical features. The 
values shown in Table 3 were calculated after outliers were filtered. These outliers 
include mean BHI greater than 1.5 or less than .8, mean V100 equal to 0%, and mean 
max dose change greater than 30%. 
Because of the varying passing rates between export scripts, different amounts of data 
were gathered for different features.  
There was no significant difference between the mean/max BHIs with the max dose taken 
at .03cc, .1cc, .2cc, and .5cc, so the mean/max BHI at .03cc was used to represent BHI.   
Time between surgery and pCT, mean/max BHI, and mean max dose change were 
significant. Age and WET change between pCT and first QACT were weakly significant. 
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Table 3 – Statistical Parameters of Numerical Features 
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3.1.2 Categorical Features 
Tables 4 and 5 show the counts of re-plans and non-replans in every category of the 
statistically significant and weakly significant categorical variables.  
Table 4 – Frequency of Re-Plans in Surgery (p = .084)  
 Count 
Category No Re-Plan Re-Plan Total 
No Surgery 41 30 71 
Surgery 47 15 62 
 
 21 
Table 5 - Frequency of Re-Plans in Surgery Margins (p = .016) 
 Count 
Category No Re-Plan Re-Plan Total 
No Margins 46 32 78 
Negative Margins 21 8 29 
Close Margins 9 4 13 
Positive Margins 11 2 13 
 
3.2 Neural Network Performance 
3.2.1 Pre-Treatment Model 
Table 6 is the classification table for the pre-treatment model. The sensitivity of this 
model is .750, and the specificity is .774. The model performed worse with the testing 
data, but still had an average accuracy of 75.7%.  
Table 6 - Classification Table for Pre-Treatment Model 





















































Figure 9 shows the ROC curve for the pre-treatment model. The model performed 
similarly for both re-plans and non-replans and had an area under the curve of .855.  
 
Figure 9 - ROC Curve for Pre-Treatment Model 
Figure 10 shows the normalized importance of features in the pre-treatment model. 
Though importance varies between different models, mean/max BHI, age, mean max 




Figure 10 - Normalized importance of features in pre-treatment model. Mean BHI, 
time between surgery and pCT, and mean max dose change were the most 
important features. 
3.2.2 On-Line Model 
Table 7 is the classification table for the on-line model. The sensitivity of this model is 
.750, and the specificity is .850. The model performed worse with the testing data, but 
still had an average accuracy of 78.9%.  
Table 7 - Classification Table for On-Line Model 






















































Figure 11 shows the ROC curve for the on-line model. The model performed similarly 
for both re-plans and non-replans and had an area under the curve of .885.  
 
Figure 11 - ROC Curve for On-Line Model 
Figure 12 shows the normalized importance of features in the on-line model. Though 
importance varies between different models, mean/max BHI, age, mean max dose 
change, and time between surgery and pCT were consistently important features. Though 
WET change between pCT and first QACT is not important in this model, it had an 
average importance of approximately ~40% across all attempts to train the model.   
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Figure 12 - Normalized importance of features in on-line model. Mean BHI, time 
between surgery and pCT, and mean max dose change were the most important 
features.  
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CHAPTER 4. DISCUSSION 
4.1 Clinical Impact of Dosimetric and Clinical Features 
Because of proton therapy’s sensitivity to anatomical changes, H&N cancers are the most 
commonly re-planned site at our institution. Reducing re-plan rates would improve 
efficiency and patient outcomes.  
This study analyzed various dosimetric and clinical features between re-plan and non-
replan groups to find parameters with statistical significance. Whether or not a feature is 
statistically significant determines whether it is a good predictor for re-plans.  
4.1.1 Significant and Weakly Significant Clinical Features 
Tables 3 and 4 show the statistical significance of clinical features. Surgery margins and 
time between surgery and CT simulation were statistically significant. Age and if patients 
had surgery are weakly significant. These results agree well with expectations because all 
these features have a direct impact on anatomical changes, which cause re-plans.  
Surgery margins describe the remaining cancer in the edges of the surgery bed. If 
margins are negative, there are no cancer cells left. If they are positive, not all the cancer 
has been removed. Close margins are when the cancer cells are close to the edge, but not 
right on it. These surgery margins impact radiotherapy because the amount of remaining 
tumor cells will determine whether the tumor bed is treated. This supports the 
relationship between margins and re-plans.  
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The time between surgery and pCT simulation has a significant impact on anatomical 
changes. Typically, missing tissue in the surgery bed is replaced with a tissue flap. 
Because the body initially rejects the flap, the flap initially swells and then shrinks. 
Because of this, patients with short times between surgery and pCT have more flap 
shrinkage occur after simulation than those with long times between surgery and 
simulation. This leads to patients with shorter time being more likely to be re-planned. 
This is supported by the data in Table 3, which shows that, on average, patients with re-
plans had times that were approximately 2 weeks shorter than patients with no re-plans.  
The weak correlation observed between age and re-plans was expected. Surucu et al, 
which produced a decision tree for predicting tumor shrinkage, found that the patient’s 
age was a good predictor for tumor shrinkage (25). This is supported by the data in Table 
3, which shows that, on average, patients with re-plans were approximately 6 years older 
than patients with no re-plans.    
The weak correlation between whether the patient had surgery and re-plans is surprising 
because, as discussed previously, surgery has an impact on anatomical changes. 
However, though surgery can impact tissue changes, it can still occur in patients who did 
not have surgery. Surgery involves the partial or full removal of the tumor. Because a 
portion of or all the tumor is removed, tumor shrinkage is less of a problem in patients 
who had surgery. The data in Table 4 supports this, with patients with and without 
surgery having re-plan rates of 24.2% and 42.3%, respectively. 
4.1.2 Non-Significant Clinical Features  
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As shown in Table 3, sex, stage, T, N, p16, time between pCT and QACT, planner, 
treatment type, and whether the patient had chemotherapy were not significant.  
The sex of the patient does not determine their sensitivity to anatomy changes. Surucu et 
al found that sex was not a good predictor for tumor shrinkage (25). The data supports 
this, with male and female patients having similar re-plan rates of 32.5% and 37.5%, 
respectively.  
No patients in our data set had metastatic tumors. This absence of variability led to the 
lack of correlation between M and re-plans.  
Re-plan rates do vary across planners, but this does not make the planner a predictor for 
re-plans. The differences in re-plan rates between planners are not large enough to expect 
any correlation between planner and re-plans.  
The time between pCT and first QACT is typically 3-4 weeks. This small variability 
likely is what caused the lack of a correlation with re-plans. This is supported by the data 
in Table 3, which shows a similar means between re-planned and non-replanned patients 
of 22 and 23 days, respectively. Another explanation for the lack of significance is that, 
by the first QACT, most anatomical changes are already detectable. This is supported by 
the weak significance of the WET change by the first QACT, shown in Table 3. This 
provides evidence that anatomical changes seen in the first QACT are already good 
predictors for re-plans, so the time between pCT and QACT is irrelevant.  
Only 2 cases out of 132 were palliative. This lack of variation in the type of therapy 
caused the lack of correlation with re-plans.  
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The non-significance of site, p16, stage, T, N, and whether the patient had chemotherapy 
were not expected.    
The relationship between site and tumor shrinkage has been observed by Sucuru et al 
(25). Because p16 varies by site, a correlation between it and re-plans was also expected. 
A possible explanation for our lack of correlation between site and re-plans is the broad 
range of sites in H&N cancer, leading to a lack of data for each site and therefore a non-
significant result.  
Tumor stage, T, and N are expected to be related to re-plans. The stage of the tumor is 
directly related to the effectiveness of treatment, and thus tumor shrinkage. T and N are 
related to re-plans similarly. A possible explanation for this lack of correlation in stage, 
T, and N is the broad range of values they take. In our data, stage, T, and N had 15, 12, 
and 12 categories, respectively. The individual data in each category is slim and thus a 
correlation cannot be established.  
Because chemotherapy has such a large impact on weight loss, it was expected to be 
significant. The data showed a large difference between the re-plans rates. Patients with 
and without chemotherapy had re-plan rates of 39.3% and 26.5%, respectively. This 
supports the expected result of patients with chemotherapy having higher re-plan rates, 
but this result is not significant. One possible explanation for this lack of significance is 
that the type of chemotherapy was not gathered when the clinical data were collected. 
Certain chemotherapies have greater impact on patient anatomy, and this information 
could have been obscured. This is supported by the literature (25).  
4.1.3 Significant and Weakly Significant Dosimetric Features 
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The significance of dosimetric features is shown in Table 3. Mean BHI, max BHI, and 
mean max dose change were all significant. WET change between pCT and the first 
QACT was weakly significant. These match well with our predictions.  
Because the BHI is the ratio of the beam’s max dose to its expected contribution, it is a 
good measure of dose heterogeneity and hotspots. When beams contribute much more 
dose than expected, anatomical changes impact the plan much more harshly than a less 
heterogenous plan. Because of this, both mean and max BHI were expected to correlate 
with re-plans. We found that the more heterogenous a plan is, the more likely it is to be 
re-planned. This is shown in Table 3. On average, patients with and without re-plans had 
a mean BHI of 1.11 and 1.09, respectively. A similar relationship is present in max BHI.  
Mean max dose change is another measure of hotspots. It describes the shift of the 
hotspot in response to density changes and anatomy shifts. A high mean max dose change 
means the plan is not very robust. As expected from less robust plans, patients with high 
mean max dose changes were more likely to be re-planned. This is supported by the data 
in Table 3. On average, Patients with and without re-plans had a mean max dose change 
of 3.22% and 2.87%, respectively.  
WET change is the most direct measure of anatomy changes. Because of this, WET 
change between the pCT and first QACT was expected to correlate with re-plans, but it 
was barely outside of the confidence interval. With more data, this feature might become 
significant.  
4.1.4 Non-Significant Dosimetric Features 
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As shown in Table 3, success rate, mean V100, and mean V100 change were not 
significant. A plausible explanation for the lack of significance is that all 3 of these 
features must be suitable before a plan is approved for treatment. Approved plans have 
high success rate and coverage as well as low coverage change, so these features do not 
differ much between patients. This is supported by Table 3. The mean success rates of re-
planned and non re-planned patients are almost equal. Though there is a difference in the 
means of re-planned and non re-planned patients for mean V100 and mean V100 change, 
this difference is not significant.  
4.2 Clinical Impact of Feature Importance in Neural Networks 
As shown in Figures 10 and 12, important features in the pre-treatment and on-line 
models were mean/max BHI, age, mean max dose change, time between surgery and 
pCT. These features were all statistically significant.  
Mean/max BHI and mean max dose change are the best plan quality parameters to use to 
predict re-plans. Age and time between surgery and pCT are the best clinical parameters.  
4.3 Clinical Impact of Neural Networks for Re-Plan Prediction 
The overall prediction accuracies shown in Tables 6 and 7 for the pre-treatment and on-
line models are large. The prediction accuracies in the testing data were worse, but not 
low enough to indicate overfitting. The sensitivity/specificities are high, which is optimal 
for good prediction models. The ROCs for both models have high area under the curve.  
In all areas, the on-line prediction model performed better than the pre-treatment model. 
This was expected because the on-line model included WET changes as an extra feature. 
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These models are high quality enough to be applied clinically. Using these models could 
reduce re-plan rates.  
4.4 Future Work 
In order to be successful, these models need to be implemented in the TPS. A python 
script could be created that allows the planner to input the necessary dosimetric and 
clinical features and output the prediction of the neural network based these parameters. 
For the on-line model, this script would be used for every QACT. The WET changes 
between the current QACT and the pCT would be inputted, allowing re-plan predictions 
to be made for every QACT. 
These models can also be refined with better feature selection. Site, stage, and TNM 
could become significant if more data is gathered or if the categories can be reduced. 
Conformity index, the ratio of the volume of the CTV covered by the prescription and the 
volume of the CTV, could also be significant.   
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CHAPTER 5. CONCLUSION 
H&N cancer is a rare, but deadly. Radiotherapy has been used for decades to treat H&N 
cancer. Recently, proton therapy has been used for treating H&N cancers due to its high 
dose conformity. Proton therapy is very sensitive to anatomy changes, and H&N patients 
often have various anatomical changes such as tumor shrinkage during treatment. 
Because of this, adaptive therapy is necessary for H&N sites, and H&N cancers are the 
most re-planned site at our institution.  
This study looked at various clinical and dosimetric features such as patient surgery and 
beam heterogeneity and determined how good of predictors they were for re-plans. Using 
these features, two neural networks for re-plan prediction were made: one before 
treatment, and one for during treatment.  
We several features that were good predictors for re-plans such as average beam 
heterogeneity, average max dose change, and the time between surgery and pCT. Both 
models performed well on their training and testing, and both have enough predictive 
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